Marta Kijanka was born on the 3rd November 1985 in Wroclaw, Poland. In 2007 she obtained Bachelor degree in Biotechnology and continued her education on the Medical Biotechnology. She participated in the Socrates/Erasmus programme at Utrecht University focusing on visualization of influenza antigens in frozen and paraffin embedded sections of the nasal cavity after intranasal vaccine application. In July 2009 she started working as research assistant at Utrecht University. In 2010 she joined the Molecular Oncology Group at Utrecht University where she started her PhD project on development and preclinical characterization of anti-HER2 nanobodies for optical imaging and therapy of breast cancer. After obtaining PhD degree she worked for almost a year at QVQ B.V. Since August 2015 until December 2017 she acted as Vice President of R&D at APO-T B.V., in January 2018 she was appointed interim CEO at APO-T B.V.